Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma.
about
Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancyAn Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of CholangiocarcinomaIntrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapiesProgression of targeted therapy in advanced cholangiocarcinomaTargeting Angiogenesis in Biliary Tract Cancers: An Open OptionA phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma.ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brainPhase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.Recent advances in the regulation of cholangiocarcinoma growthHDAC6 inhibition restores ciliary expression and decreases tumor growthComparison of effects of anti-angiogenic agents in the zebrafish efficacy-toxicity model for translational anti-angiogenic drug discovery.Mouse model for ROS1-rearranged lung cancerQuantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma.Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinomaPrognostic value of neutrophil distribution in cholangiocarcinoma.Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N'-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily.Intravoxel Incoherent Motion Diffusion-weighted Magnetic Resonance Imaging for Monitoring the Early Response to ZD6474 from Nasopharyngeal Carcinoma in Nude Mouse.Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives.Targeted therapy for biliary tract cancer.Targeted therapy in biliary tract cancer: 2009 update.Vascular factors, angiogenesis and biliary tract diseaseSerum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implicationsA perspective on molecular therapy in cholangiocarcinoma: present status and future directions.Vandetanib and ADAM inhibitors synergistically attenuate the pathological migration of EBV-infected retinal pigment epithelial cells by regulating the VEGF-mediated MAPK pathway.Cancer stem cells: the development of new cancer therapeutics.Targeted therapy for biliary tract cancers.Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales.New and emerging treatment options for biliary tract cancer.Hydrodynamic transfection for generation of novel mouse models for liver cancer research.Sulfated Galactans from Red Seaweed Gracilaria fisheri Target EGFR and Inhibit Cholangiocarcinoma Cell Proliferation.Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications.The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines.Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.Prognostic Value of C-met Expression in Cholangiocarcinoma.Expression and activation of EGFR and STAT3 during the multistage carcinogenesis of intrahepatic cholangiocarcinoma induced by 3'-methyl-4 dimethylaminoazobenzene in rats.A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study.Cholangiocarcinoma pathogenesis: Role of the tumor microenvironment.Interaction of a tyrosine kinase inhibitor, vandetanib with human serum albumin as studied by fluorescence quenching and molecular docking.Clinicopathological significance of growth factors and their receptors as potential therapeutic targets for biliary tract carcinoma.Inhibitor of MEK1/2, selumetinib, for biliary tract cancer.
P2860
Q26767120-9FE5B5FB-4CE0-4542-8AE3-99AFFD5D0CE4Q26784091-83634057-85C6-4BD9-B8E8-57592CC13418Q27002547-609EAAC7-02A7-4496-96CA-7D594137C941Q27016150-A8D6D660-7FB7-4053-B866-CCE9DD931F8FQ30398807-6008073F-B219-459A-AA41-C9F72906411BQ33411061-D9D944C4-99F3-4D7D-9034-EFB65870A5FCQ33870872-0338CB50-2FB7-4978-8773-812D1ABA66ECQ33994406-6DE7F5C9-97AF-4401-8C6C-357AEDF005D4Q33994814-7AE116A4-E90F-434C-B493-88756E50C651Q34035361-CAA4F10F-3549-4016-830D-A220169F4A97Q34094154-4C9B8F3A-A914-4A90-833F-A236AE9444D6Q34589721-1C2AAA12-31DB-407A-9095-FF100D321EA5Q35070321-40994BC3-932F-40B3-9FA9-ED9095CCBA31Q35108386-6A327865-F42F-4127-BB10-BBB5C71978B1Q35534078-863E0DD5-C3EA-4249-88C5-84FB214EF709Q36280842-F6C9531E-0D52-46C4-8DF6-4DE7CEDBFA37Q36287670-67E99C5A-DEC5-4D48-99DD-2DA333E11408Q36962011-39152055-35E6-4DBA-BAA3-23A22874E010Q37132750-81013588-4B34-417A-8F95-F799439E30DAQ37650623-2530DCFF-DD94-4ACC-A60B-C03874C5ADDCQ37671557-EF3E3711-E38D-412D-8C88-8004BFAFDA51Q37706763-E650E970-52F3-4C93-BAE6-28BDF073D0CFQ37719383-A5F0550A-1A63-41D9-AC45-441D104AD840Q37734665-07E3F9CD-0930-42B4-9B93-6AE131D70F29Q37861207-CD3CA553-3819-4867-8209-85CF93074EACQ37982650-60800AB2-4B24-41BC-8D04-AC71D98252E6Q38130312-0BAA9655-9647-4D62-9E61-69B335B29B06Q38160836-6CEF0B62-68ED-4019-9EC8-16958D6E0370Q38183539-7E1B170E-613A-4981-977B-7C949338F7BCQ38849599-16D05682-E318-46E2-9BA4-72033F8920D5Q39289707-C5D71E60-E473-42BA-8A68-1D4DC7AF49A5Q39422598-652D627C-7EC4-4218-B288-8338AA286C25Q39683530-6616D866-FCD4-4F7D-BF2D-7CBB18ED7174Q41073453-A0C3F093-06C6-4634-8ABC-A98FC8D51F03Q41105428-CB388821-E885-48D4-B956-B637930D4786Q41652822-D65C80B3-237F-4EFA-B5DF-4E0E470C5601Q42029380-8D1E264F-4B6C-4A9E-AC17-F08D110BC50EQ53554556-B23D6B20-859D-420C-8CFC-22258F294FA1Q54533998-0781CF8A-3943-4923-8281-841CB18C9724Q54561378-1E35281D-B969-4512-92D5-797ED783B6CE
P2860
Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vandetanib (ZD6474), an inhibi ...... py against cholangiocarcinoma.
@en
Vandetanib (ZD6474), an inhibi ...... py against cholangiocarcinoma.
@nl
type
label
Vandetanib (ZD6474), an inhibi ...... py against cholangiocarcinoma.
@en
Vandetanib (ZD6474), an inhibi ...... py against cholangiocarcinoma.
@nl
prefLabel
Vandetanib (ZD6474), an inhibi ...... py against cholangiocarcinoma.
@en
Vandetanib (ZD6474), an inhibi ...... py against cholangiocarcinoma.
@nl
P2093
P2860
P356
P1476
Vandetanib (ZD6474), an inhibi ...... py against cholangiocarcinoma.
@en
P2093
D Yoshikawa
S Hirohashi
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604988
P407
P577
2009-03-24T00:00:00Z